Immunotherapy against several tumors including neuronal and brain tumors
A method of treating a patient who has brain cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has brain cancer. A method of treating a patient who has brain cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the brain cancer.
1. A method of treating glioblastoma in a HLA-A*02+ patient having glioblastoma overexpressing a IGF2BP3 polypeptide comprising the amino acid sequence of SEQ ID NO: 14 and presenting at its surface a peptide consisting of SEQ ID NO: 14 in the context of a complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate the cancer cells, wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 14 in the context of a complex with an MHC class I molecule in vitro.
2. The method of claim 1 , wherein the cytotoxic T cells produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 14 in the context of a complex with an MHC class I molecule are cytotoxic T cells autologous to the patient.
3. The method of claim 1 , wherein the cytotoxic T cells produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 14 in the context of a complex with an MHC class I molecule are cytotoxic T cells obtained from a healthy donor.
4. The method of claim 1 , wherein the cytotoxic T cells produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 14 in the context of a complex with an MHC class I molecule are cytotoxic T cells isolated from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , wherein the cytotoxic T cells produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 14 in the context of a complex with an MHC class I molecule are expanded in vitro before being administered to the patient.
6. The method of claim 5 , wherein the cytotoxic T cells are expanded in vitro in the presence of an anti-CD28 antibody and IL-12.
7. The method of claim 1 , wherein the effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate the cancer cells is administered in the form of a composition.
8. The method of claim 1 , wherein said composition further comprises an adjuvant.
9. The method of claim 8 , wherein said adjuvant is selected from imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, interferon-alpha, CpG oligonucleotides, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG) and virosomes.
10. The method of claim 1 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
11. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide consisting of SEQ ID NO: 14.
12. The method of claim 1 , wherein the antigen presenting cell is an artificial antigen presenting cell (aAPC) comprising an anti-CD28 antibody coupled to its surface.